GH Secretagogues

Tesamorelin

FDA approved

Also known as: Egrifta, Egrifta SV

FDA-approved GHRH analog with the strongest visceral fat reduction data.

Open in AppAsk AI Advisor

Mechanism

GHRH analog. FDA-approved GHRH analog with the strongest visceral fat reduction data. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.

Peer-Reviewed Studies (3)

Tesamorelin for HIV-Associated Lipodystrophy (Pivotal)

NEJM · 2007

18% visceral adipose reduction at 26 weeks.

PubMed PMID 17968058 →

Tesamorelin Effects on Liver Fat in HIV-Associated NAFLD

Lancet HIV · 2019

32% liver fat reduction over 12 months.

PubMed PMID 31010708 →

Tesamorelin and Cognitive Function in HIV

JAIDS · 2018

Improved cognitive function in HIV-positive adults.

PubMed PMID 30067561 →

Related Compounds

Sermorelin

First-generation GHRH analog — short half-life produces clean, physiological GH pulses.

CJC-1295 (with DAC)

Long-acting GHRH analog — DAC modification extends half-life to 6+ days.

Mod GRF 1-29 (CJC-1295 no DAC)

The pulsatile cousin of CJC-1295 — short half-life, clean pulses, ideal stack with ipamorelin.

Ipamorelin

The cleanest GHRP — selective GH release with no significant cortisol or prolactin elevation.

GHRP-2

Stronger GH release than ipamorelin, with cortisol and appetite trade-offs.

MK-677 (Ibutamoren)

The only orally bioavailable GH secretagogue — sustained GH/IGF-1 elevation in pill form.